The company presented a poster at the ACG meeting this week that reported over 80 percent sensitivity in a retrospective cohort with a majority of early-stage cancers.
The German company validated the panel, which focuses on actionable results, in a 300-participant clinical study in collaboration with Robert-Bosch-Hospital in Stuttgart.
The team demonstrated that the approach can yield high sensitivity while maintaining near-perfect specificity, but it must now replicate the early results in a much larger study.
The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.
The Associated Press reports that gene-edited food may soon be for sale.
The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.
In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.